Sarepta Therapeutics exercised its option to acquire Nationwide Children’s gene therapy spinout Myonexus Therapeutics after paying at least $60m for the right in May 2018.

Myonexus Therapeutics, a US-based gene therapy developer spun out of Nationwide Children’s Hospital, an affiliate of Ohio State University, is to be acquired by rare disease medicine producer Sarepta Therapeutics for $165m. The deal is subject to the fulfilment of certain closing conditions. Founded in 2017, Myonexus Therapeutics is working on five gene therapies for…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.